The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Cancer gene therapy using a survivin mutant adenovirus
Open accessAbstract
We have constructed a replication-deficient adenovirus encoding a nonphosphorylatable Thr(34)-->Ala mutant of the apoptosis inhibitor survivin (pAd-T34A) to target tumor cell viability in vitro and in vivo. Infection with pAd-T34A caused spontaneous apoptosis in cell lines of breast, cervical, prostate, lung, and colorectal cancer. In contrast, pAd-T34A did not affect cell viability of proliferating normal human cells, including fibroblasts, endothelium, or smooth muscle cells. Infection of tumor cells with pAd-T34A resulted in cytochrome c release from mitochondria, cleavage of approximately 46-kDa upstream caspase-9, processing of caspase-3 to the active subunits of approximately 17 and 19 kDa, and increased caspase-3 catalytic activity. When compared with chemotherapeutic regimens, pAd-T34A was as effective as taxol and considerably more effective than adriamycin in induction of tumor cell apoptosis and enhanced taxol-induced cell death. In three xenograft breast cancer models in immunodeficient mice, pAd-T34A suppressed de novo tumor formation, inhibited by approximately 40% the growth of established tumors, and reduced intraperitoneal tumor dissemination. Tumors injected with pAd-T34A exhibited loss of proliferating cells and massive apoptosis by in situ internucleosomal DNA fragmentation. These data suggest that adenoviral targeting of the survivin pathway may provide a novel approach for selective cancer gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Self-citationMitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103
IAP family proteins---suppressors of apoptosis
Deveraux, Q. L., & Reed, J. C. (1999) · Genes & Development · doi:10.1101/gad.13.3.239 · Cited by 2,551
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Self-citationAn Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Cited by
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Self-citationSurvivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Self-citationSurvivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Self-citationApoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice
Schimmer, A. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1918 · Cited by 512
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
The molecular basis and potential role of survivin in cancer diagnosis and therapy
Altieri, D. C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02243-2 · Cited by 412
Self-citationMitochondrial survivin inhibits apoptosis and promotes tumorigenesis
Dohi, T., Beltrami, E., Wall, N. R., Plescia, J., & Altieri, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422222 · Cited by 405
Self-citationE-cadherin: Its dysregulation in carcinogenesis and clinical implications
Wong, S. H. M., Fang, C. M., Chuah, L.-H., Leong, C. O., & Ngai, S. C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.010 · Cited by 400
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 379
Song, Z., Yao, X., & Wu, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300957200 · Cited by 363
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Survivin and molecular pathogenesis of colorectal cancer
Kim, P. J., Plescia, J., Clevers, H., Fearon, E. R., & Altieri, D. C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13910-4 · Cited by 323
Self-citationA p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Self-citationSurvivin study: What is the next wave?
Li, F. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10327 · Cited by 309
Apoptosis-based therapies and drug targets
Fischer, U., & Schulze-Osthoff, K. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 282
A Time to Kill: Targeting Apoptosis in Cancer
Koff, J., Ramachandiran, S., & Bernal-Mizrachi, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022942 · Cited by 279
Schmidt, S. M., Schag, K., Müller, M. R., Weck, M. M., Appel, S., Kanz, L., Grünebach, F., & Brossart, P. (2003) · Blood · doi:10.1182/blood-2002-08-2554 · Cited by 277
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F., & Daidone, M. G. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8518-3 · Cited by 275
Survivin: A promising tumor biomarker
Duffy, M. J., O’Donovan, N., Brennan, D. J., Gallagher, W. M., & Ryan, B. M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.020 · Cited by 267
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer
NACHMIAS, B., ASHHAB, Y., & BENYEHUDA, D. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.002 · Cited by 266
New Approaches and Therapeutics Targeting Apoptosis in Disease
Fischer, U., & Schulze-Osthoff, K. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.6 · Cited by 257
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
Kim, R., Tanabe, K., Uchida, Y., Emi, M., Inoue, H., & Toge, T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0522-7 · Cited by 253
Self-citationUltraviolet radiation-induced apoptosis in keratinocytes: On the role of cytosolic factors
Assefa, Z., Van Laethem, A., Garmyn, M., & Agostinis, P. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.04.001 · Cited by 212
Aspe, J. R., Diaz Osterman, C. J., Jutzy, J. M. S., Deshields, S., Whang, S., & Wall, N. R. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.23244 · Cited by 126
Self-citationVenkatesan, B., Prabhu, S. D., Venkatachalam, K., Mummidi, S., Valente, A. J., Clark, R. A., Delafontaine, P., & Chandrasekar, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.005 · Cited by 105
Recent Patents on Anti-Telomerase Cancer Therapy
Agrawal, A., Dang, S., & Gabrani, R. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212798357958 · Cited by 61
Dohi, T., Salz, W., Costa, M., Ariyan, C., Basadonna, G. P., & Altieri, D. C. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400640 · Cited by 32
Self-citation
Metadata
- Authors
- Mesri, M., Wall, N. R., Li, J., Kim, R. W., & Altieri, D. C.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-10-01
- Volume
- 108
- Issue
- 7
- Pages
- 981-990
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2059421587
- Cited by
- 337
- References
- 41
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.